Filed in archive
Corporate and Industrial News
, Drugs, Vaccines and Therapeutics
by ruth on February 28, 2006

"This significant infusion of equity capital will be utilized to advance our proprietary pipeline of novel therapeutics through clinical trials, including both MD-1100 and our Phase 1 cholesterol absorption inhibitor MD-0727, " said Peter Hecht, CEO of Microbia. "Both of these innovative oral drug candidates - which target the needs of millions of patients - have shown early potential in human studies, and we are committed to their aggressive, comprehensive development."
MD-1100 is a drug dandidate for chronic idiopathic constipation (CIC) and an ongoing Phase 2 trial is being conducted in patients with constipation-predominant irritable bowel syndrome (IBS-C).
Read more about Microbia and the venture funding from the Boston Globe.
Tags:
gastrointestinal
bowel
biotech
microbia
clinical
clinical+trials
through+clinical
microbia+raises
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/16475
Mr Wong
Vote for Microbia Raises $75M To Advance IBS Drug Candidate Through Clinical Trials:
|
Rating: 6.00 out of 2 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







